Hepatic enhancement in cirrhosis in the portal venous phase: what are the differences between gadoxetate disodium and gadobenate dimeglumine?

Federica VernuccioRoberto CannellaCecilia GozzoValeria GrecoMassimo MidiriAlessandro FurlanAn TangGiuseppe Brancatelli

Published in: Abdominal radiology (New York) (2021)

In cirrhotic patients, gadoxetate disodium yielded lower enhancement of the hepatic parenchyma and lower contrast of the portal vein than gadobenate dimeglumine in PVP.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
magnetic resonance
prognostic factors
peritoneal dialysis
patient reported outcomes